University of Bordeaux
Welcome,         Profile    Billing    Logout  
 8 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LEDINGHEN, Victor DE
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed
2
42
Europe, US
IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
03/24
06/24
NCT04594694 / 2018-002575-17: Study of OCA in Combination with BZF Evaluating Efficacy, Safety, and Tolerability in Participants with PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
10/25
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT03695796: French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)

Recruiting
N/A
1000
Europe
biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank
University Hospital, Angers
NAFLD
11/24
12/24
PREPCOV, NCT04481633: Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection

Recruiting
N/A
800
Europe
COVID 19 serology, COVID 19 Self-Questionnaire
University Hospital, Toulouse
COVID-19
03/22
03/22
ARIAPUMP, NCT03506893: Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients

Recruiting
N/A
90
Europe
Alphapump, Ascites puncture
University Hospital, Grenoble
Ascites, Paracentesis, Cirrhosis
12/22
12/25
SCREANIT, NCT05880173: SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population

Recruiting
N/A
502
Europe
FIB4
University Hospital, Angers
Screening, Advanced Liver Fibrosis
01/25
01/25
PRO-SURFASA, NCT05473403: Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis

Not yet recruiting
N/A
150
Europe
Corticosteroid therapy
Assistance Publique - HĂ´pitaux de Paris
Liver Failure, Acute, Hepatitis, Autoimmune, Organ Dysfunction Scores, Risk Factors
05/27
06/28
BuleDelta, NCT04166266: National Cohort of Patients Co-infected with Hepatitis B and Delta Viruses

Recruiting
N/A
800
Europe
Blood draw for the laboratory assessment
ANRS, Emerging Infectious Diseases
Hepatitis D, Chronic, Hepatitis B, Chronic
12/27
06/28
NCT04615091: Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Recruiting
N/A
250
Europe, Canada, US, RoW
Azienda Ospedaliera Universitaria Integrata Verona
Advanced Chronic Liver Disease, Surgery--Complications
10/21
08/22

Download Options